HIV Therapeutics Market

2019
HIV Therapeutics Market
HIV spreads through exchange of fluids with
some infected individual, for example, blood
exchange or imparting needles to somebody
who is HIV infected
Market Data Forecast
6/27/2019
HIV Therapeutics Market Overview:
HIV Therapeutics Market was worth USD 13.57 billion in 2018 and estimated to be
growing at a CAGR of 1.4%, to reach USD 14.55 billion by 2023. The human
immunodeficiency Virus (HIV) infection refers to a kind of retrovirus that causes
(AIDS). HIV affects some immune cells and it weakens immune system bringing about
loss of capacity to fight against the organisms that causes diseases.HIV spreads through
exchange of fluids with some infected individual, for example, blood exchange or
imparting needles to somebody who is HIV infected. Additionally, HIV can spread from
infected mother to child during pregnancy. Here are some of the symptoms of HIV
disease are slight fever, weakness, swollen glands, cerebral pains and muscle hurts.
Integrase inhibitors section is expected to be the rapid growing class of antiretroviral
medications owing to the normal dispatch of extra integrase inhibitors by major players,
for example, Gilead Sciences, In., Merck and Co., Inc.
HIV Therapeutics Market Drivers and Restraints:
Increasing number of HIV affected cases, innovative advancement in HIV diagnosis and
therapeutics, ascend in research exercises for developing HIV immunizations and not
aware about the methods of transmission of the infection are driving the worldwide
market for HIV therapeutics. Moreover, increase awareness about the accessibility of
HIV therapeutics in the market and cost effective sedate treatments for HIV are driving
the worldwide HIV therapeutics market. However, different variables, for example,
disappointment of treatment sometimes, absence of gifted experts and presentation of
non-specific medications in the market are major restraints the HIV therapeutics
market.
To know more, click on the link below:
https://www.marketdataforecast.com/market-reports/global-hiv-therapeutics-market
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis
(DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Introduction
5.1.2 integrase inhibitor
5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor
5.1.4 non-nucleoside turn around transcriptase inhibitor
5.1.5 HIV-1 protease inhibitor
5.1.6 pharmacokinetic enhancer
5.1.7 passage inhibitor
5.1.8 Y-o-Y Growth Analysis, Drug class
5.1.9 Market Attractiveness Analysis, Drug class
5.1.10 Market Share Analysis, Drug class
5.2 Application
5.2.1 Introduction
5.2.2 HIV Type-1
5.2.3 HIV Type-2
5.2.4 Y-o-Y Growth Analysis, Application
5.2.5 Market Attractiveness Analysis, Application
5.2.6 Market Share Analysis, Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 Drug Class
6.1.3.3 HIV TYPE 1&2
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 Drug Class
6.1.4.3 HIV TYPE 1&2
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 Drug Class
6.1.5.3 HIV TYPE 1&2
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
8.10 Retractable Technologies
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Geographical Analysis:
The HIV Therapeutics Market is broadly categorized into Type (Nucleoside/tide reverse
transcriptase inhibitors or nucleoside/tide analogues, Non-nucleoside reverse
transcriptase inhibitors, Protease inhibitors, Integrase [strand transfer] inhibitors,
CCR5 inhibitors, Fusion inhibitors). And on the basis of Application (HIV Type-1&2).
On the basis of geography, the global market is analyzed under various regions namely
North America, Europe, Asia-Pacific, Middle East and Africa, Latin America. North
America, trailed by Europe, has the highest market share for HIV therapeutics because
of affordability and availability of costly treatment for HIV infections and developments
in medication treatments in this region. Asia is expected to show high development rate
in the HIV therapeutics market in next couple of years because of increasing number of
HIV affected people and expanding research exercises for creating HIV medications and
immunizations in the region.
Important Market Players:
Some of the major companies dominating the market, by their products and services
include GlaxoSmithKline, Bristol-Myers Squibb, Pfizer and Boehringer Ingelheim.
Other organizations having huge presence in HIV therapeutics market are Merck,
Hoffmann-La Roche and Gilead Sciences.
View a sample and decide @ https://www.marketdataforecast.com/marketreports/global-hiv-therapeutics-market#request_sample
The Scope of the report:
This report offers the current product and services market evaluation and the future
estimation of the market. It helps us understand the market better through size
anticipation and CAGR calculation to estimate the next market. It has a broader
segmentation for better understanding of the enterprising of the market at a low level by
segregating the market into smaller sectors.
About Us:
Market Data Forecast is a firm working in the areas of market research, business
intelligence and consulting. We have rich experience in research and consulting for
various business domains to cater to the needs of both individual and corporate clients.
For more information:
Abhishek Shukla
Sales Manager at Market Data Forecast
Email: [email protected]

HIV Therapeutics Market By Type (Nucleoside/tide Reverse Transcriptase Inhibitors Or Nucleoside/tide Analogues, Non-nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase [strand Transfer] Inhibitors, CCR5 Inhibitors, Fusion Inhibitors)

Download Report